Development of Therapeutic dsP21-322 for Cancer Treatment.

about

Upregulation of E‑cadherin expression mediated by a novel dsRNA suppresses the growth and metastasis of bladder cancer cells by inhibiting β-catenin/TCF target genes.

P2860

Q52331241-9E26D37A-C42C-4BD6-B128-4D355A46445C

P2860

Development of Therapeutic dsP21-322 for Cancer Treatment.

Item

http://www.wikidata.org/entity/Q39390094

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Development of Therapeutic dsP21-322 for Cancer Treatment.

@en

Development of Therapeutic dsP21-322 for Cancer Treatment.

@nl

type

Item

label

Development of Therapeutic dsP21-322 for Cancer Treatment.

@en

Development of Therapeutic dsP21-322 for Cancer Treatment.

@nl

prefLabel

Development of Therapeutic dsP21-322 for Cancer Treatment.

@en

Development of Therapeutic dsP21-322 for Cancer Treatment.

@nl

P1476

Development of Therapeutic dsP21-322 for Cancer Treatment.

@en

P2093

Gongcheng Li

http://www.w3.org/2001/XMLSchema#string

Jin-Chun Xing

http://www.w3.org/2001/XMLSchema#string

Long-Cheng Li

http://www.w3.org/2001/XMLSchema#string

Moo Rim Kang

http://www.w3.org/2001/XMLSchema#string

Tiejun Pan

http://www.w3.org/2001/XMLSchema#string

P2860

RNAa is conserved in mammalian cells

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases

MicroRNA-373 induces expression of genes with complementary promoter sequences

Small dsRNAs induce transcriptional activation in human cells

The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA

p21 in cancer: intricate networks and multiple activities

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics.

p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell.

A status report on RNAi therapeutics.

Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.

P304

217-229

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/978-981-10-4310-9_16

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

983

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28639203

http://www.w3.org/2001/XMLSchema#string

Development of Therapeutic dsP21-322 for Cancer Treatment.

about

P2860

P2860

Development of Therapeutic dsP21-322 for Cancer Treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698